From: Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments
Treatment | Duration | Mammary cancer incidence | Rats with mammary cancer (%) | Average number of cancers per rat |
---|---|---|---|---|
Control | 3 weeks | 8/10 | 80 | 1.7 ± 0.4 |
30 mg estriol | 1 week | 10/12 | 83 | 1.6 ± 0.3 |
200 μg estriol | 1 week | 11/11 | 100 | 1.7 ± 0.3 |
30 mg estriol + 30 mg progesterone | 1 week | 7/12 | 58 | 1.2 ± 0.3 |
200 μg estriol + 30 mg progesterone | 1 week | 9/12 | 75 | 1.6 ± 0.3 |
30 mg estriol | 3 weeks | 7/11 | 64 | 1.0 ± 0.3 |
200 μg estriol | 3 weeks | 9/12 | 75 | 1.6 ± 0.3 |
30 mg estriol + 30 mg progesterone | 3 weeks | 3/12* | 25 | 0.4 ± 0.2* |
200 μg estriol + 30 mg progesterone | 3 weeks | 9/11 | 82 | 2.0 ± 0.4 |